Campusano C, López J M, Campino C, Cárdenas I, Rojas A
Departamento de Endocrinología, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago-Chile.
Rev Med Chil. 2000 Apr;128(4):387-91.
Calcitonin is specially indicated for the treatment of osteoporosis in women that cannot receive estrogen replacement therapy or that have a high bone turnover rate.
To study the effects of low intranasal calcitonin doses on bone remodeling in postmenopausal women with a high bone turnover.
Forty one healthy women aged 56 +/- 6 years old, with a mean lapse after menopause of 7.6 +/- 6.5 years and with a high bone turnover rate, evidenced by an urinary hydroxyproline (mg/dl)/creatinine (g/dl) ratio of 52.4 +/- 7.2, were studied. They were randomly assigned to receive 100 or 50 U/calcitonin thrice a week during 3 months or to a control group that received placebo. All received 500 mg/day calcium carbonate. Urinary hydroxyproline/creatinine ratio was measured a 0, 15, 30, 60 and 90 days. Plasma bone fraction of alkanine phosphatases was measured at 0, 30 and 90 days.
Initial urinary hydroxyproline/creatinine ratio and plasma bone fraction of alkanine phosphatases were similar in all study groups and there was no change in these parameters during the study period.
Intranasal calcitonin in doses of 100 U thrice a week or less, does not modify accelerated bone turnover in postmenopausal women.
降钙素特别适用于无法接受雌激素替代疗法或骨转换率高的女性骨质疏松症的治疗。
研究低剂量鼻内降钙素对骨转换率高的绝经后女性骨重塑的影响。
研究了41名年龄在56±6岁的健康女性，她们绝经后的平均时间为7.6±6.5年，骨转换率高，尿羟脯氨酸（mg/dl）/肌酐（g/dl）比值为52.4±7.2可证明这一点。她们被随机分配，在3个月内每周三次接受100或50 U降钙素，或分配至接受安慰剂的对照组。所有人均每天服用500 mg碳酸钙。在第0、15、30、60和90天测量尿羟脯氨酸/肌酐比值。在第0、30和90天测量血浆碱性磷酸酶的骨分数。
所有研究组的初始尿羟脯氨酸/肌酐比值和血浆碱性磷酸酶的骨分数相似，且在研究期间这些参数没有变化。
每周三次100 U或更低剂量的鼻内降钙素不会改变绝经后女性加速的骨转换。
Zotero 插件